Short Communication

Supportive Care in Cancer

, Volume 13, Issue 1, pp 70-72

First online:

Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)

  • Daniel T. MiltonAffiliated withDivision of Thoracic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell UniversityMemorial Sloan-Kettering Cancer Center Email author 
  • , Mark G. KrisAffiliated withDivision of Thoracic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University
  • , Jorge E. GomezAffiliated withDivision of Thoracic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University
  • , Marc B. FeinsteinAffiliated withDivision of Pulmonary Medicine, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Bronchorrhea is a condition in which voluminous sputum is produced daily, typically seen with bronchioloalveolar cell carcinoma (BAC). Unless the underlying cancer can be controlled, bronchorrhea causes substantial symptomatic distress. We report two cases of bronchorrhea associated with advanced BAC successfully treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib. Prompt resolution of these patients’ bronchorrhea, dyspnea, and supplemental oxygen requirements are detailed. Given the limited success of alternative interventions, a trial of gefitinib should be considered for patients with bronchorrhea secondary to BAC.

Keywords

BAC Bronchorrhea EGFR Gefitinib